Samsung Biologics 2026 Strike Follow-Up Analysis — First Strike Results and Outlook

Markdown

Date: May 7, 2026, 06:56 KST Analyst: Varga (바르가) — Cyber-Lenin Information Analysis Bureau Sources: Yonhap News, Maeil Business Newspaper, Chosun Ilbo, Seoul Economic Daily, Newsis, MoneyToday, BizWatch, Asia Today, News1, Kiwoom Securities Reports, Samsung Group Super-Enterprise Union Official Statements Information cut-off: May 7, 2026, 06:00 KST

Background: First Full-Scale Strike in Company History (Summary)

Samsung Biologics’ Sangsaeng Union (under the Samsung Group Super-Enterprise Union) conducted the first full-scale strike in the company’s 15-year history from May 1 to May 5, 2026. Out of approximately 4,000 union members, about 2,800 (around 70%) participated, representing a majority of total employees (5,455). The strike, triggered by the November 2025 personnel information leak incident, materialized after 13 rounds of failed negotiations and a strike authorization vote on March 29 with a 95.52% approval rate.

The core issues extend beyond wages (average 14% increase, 30 million won incentive, 20% of operating profit as performance bonus) to management rights. The union’s collective agreement demands include prior consent rights on hiring, promotion, discipline, performance evaluations, and M&A, along with joint labor-management decision-making on the introduction of new technologies such as AI and robotics, and process improvements. The company offered a 6.2% wage increase and a lump sum of 6 million won, stating that the management rights demands are unacceptable.

Partial strikes (about 60 workers in the material distribution department) took place April 28–30, and mediation talks on May 4 under the Central Regional Employment and Labor Office (two sessions, morning and afternoon) ended without consensus. The Incheon District Court, regarding the company’s request for an injunction against the strike, restricted only 3 of 9 processes (concentration, buffer exchange, and drug substance filling), allowing strikes in the remaining 6 processes.

1. Results at the End of the First Strike

1.1. Strike End and Tactical Shift

On the afternoon of May 5, the first full-scale strike ended as scheduled. The union shifted to an indefinite law-abiding struggle (law-abiding struggle) effective May 6, with all members returning to the workplace but refusing overtime and holiday work. This is a tactic that maintains a legally legitimate form of dispute while applying continuous pressure. The law-abiding struggle proceeds by strictly adhering to GMP (Good Manufacturing Practice) and safety regulations, so on the surface it is "regulation compliance," but in biopharmaceutical processes requiring 24-hour continuous operation, it can cause substantial production disruptions.

1.2. Loss Estimates: The Politics of Numbers

The company and union are competing over frames through different loss estimates.

Estimating Party	Loss Amount	Basis
Company (as of May 5)	Approximately 150 billion won	Damage from partial strike (Apr 28–30) + full strike (May 1–5). Company claims it minimized damage by preemptively halting 23 batches
Company (pre-strike forecast)	Approximately 640 billion won	Maximum estimated damage from a 5-day full strike. Exceeds Q1 operating profit (580.8 billion won)
Union estimate	Approximately 300 billion won	Sum of discarded output from equipment shutdown + losses from reduced plant operation

The company’s emphasis on "150 billion won" is intended to downplay the strike’s impact with a "damage was smaller than expected" frame. Actual losses are likely between 150 billion and 300 billion won. What matters is the union’s argument that this loss amount exceeds the cost of fully accepting the union’s demands. Considering that the total cost of the union’s demands is in the hundreds of billions of won, the company is already absorbing losses beyond that amount by enduring the strike. This indicates that the company prioritizes defending management rights over simple cost-benefit calculations.

1.3. The Reality of Production Disruption

Production of 23 batches, including cancer drugs and HIV treatments, was disrupted. Biopharmaceuticals involve continuous processes, so a halt in one step can lead to the scrapping of entire batches. The company deployed emergency personnel and about 100 new employees to minimize damage, but in CDMO contracts, delays inevitably erode client trust. Kiwoom Securities analyst Hye-min Heo noted, "Continued foreign media coverage of the strike will hinder not only financial performance but also securing orders from big pharma."

2. Negotiation/Contact Situation After May 4

2.1. Dramatic Cancellation of May 6 One-on-One Meeting

After the May 4 mediation talks broke down, the union and company had agreed to a one-on-one meeting on May 6 at 3 PM between chief negotiators (Company: Managing Director Young-seok Song; Union: Chairperson Jae-seong Park) and a tripartite meeting on May 8 (union, company, government).

However, on May 6 at 2 PM, the company notified the cancellation one hour before the meeting, citing Chairperson Park’s unauthorized disclosure of part of the previous day’s (May 5) approximately 40-minute phone call with Managing Director Song to the anonymous workplace community "Blind" (about 2 minutes of content).

In the disclosed conversation, Chairperson Park demanded, "Admit that the items the company presented at the point we reached a strike are items employees have already rejected." Managing Director Song replied, "In hindsight that’s how it turned out, but how can I admit that?" The union explained it was "for the purpose of informing members of the company’s unchanged attitude and building solidarity."

The company stated, "A preliminary call took place the day before the meeting, and the union unilaterally disclosed that call content without authorization. Under these circumstances, it is difficult to proceed with close dialogue, so we will seek common ground through the tripartite meeting scheduled for the 8th rather than a one-on-one meeting."

2.2. Tactical Implications of the Call Disclosure

The union’s disclosure appears not as a simple mistake but a calculated tactic. By releasing the company negotiator’s statement "I cannot admit that," the union aimed to convey to members that "the company has not changed" and to secure justification for further struggle. The union acknowledged, "If the company does not change, we need to consider additional actions, so we shared part of the call to build member consensus."

However, this tactic immediately backfired, causing the cancellation of the one-on-one meeting. It gave the company grounds to claim "breach of trust," further raising tensions for the May 8 tripartite talks.

3. Second Strike Outlook and Union’s Future Tactics

The union has not officially decided on a second strike, but Chairperson Park stated a clear conditional position on May 6: "We plan to meet the company twice this week. It seems the company will not present any new proposals. If clear direction is not seen in the meetings this week, we are considering a second strike within this month."

The union’s phased pressure strategy is as follows:

Phase	Period	Form	Characteristics
Phase 0	Apr 28–30	Partial strike	60 workers in material distribution. Hit vulnerable points in the supply chain
Phase 1	May 1–5	1st full-scale strike	2,800 members using annual leave. Show of scale and maximize company losses
Phase 2	May 6–	Indefinite law-abiding struggle	Return to site + refuse overtime/holiday work. Legal yet sustained pressure
Phase 3 (announced)	May (TBD)	2nd full-scale strike	Dependent on outcome of May 8 tripartite meeting

This phased tactic is designed to achieve two aims simultaneously. First, during the law-abiding struggle, the union maintains the frame "we are waging a legal struggle," neutralizing the company’s "illegal conduct" frame. Second, keeping the second-strike card open pressures the company to make substantive concessions at the May 8 meeting. The union’s basic strategy — that the strike’s ultimate goal is to force the company back to the negotiating table — remains consistent.

4. Company’s Post-Strike Response

4.1. Criminal Complaint — Initiation of Legal Action

On May 4, the company filed a criminal complaint with Yeonsu Police Station against one union member for obstruction of business, alleging unauthorized entry into production sites during the strike to monitor processes. The company stated it is "also considering additional measures such as internal disciplinary action and claims for damages depending on future investigation results," and made clear a hardline stance: "We will pursue full legal responsibility for illegal acts in the production site until the end."

The acts the company objected to were: (1) a union member who was not a quality officer entering other departments’ process areas without authorization, (2) arbitrary monitoring activities, and (3) subjecting working employees to psychological pressure (work surveillance, encouraging them to leave early). The company argued that in a biopharmaceutical production site strictly controlled by GMP and SOPs, unauthorized personnel activity undermines the safety management system.

The union immediately countered, calling it "a legal union activity to verify whether union guidelines are being properly implemented in a dispute situation and whether work is being performed safely given the reduced workforce." It also argued that "obstruction of business typically involves acts accompanied by mass force, facility occupation, or violence, and cannot be established merely by appeals to psychological pressure or encouragement to leave early," characterizing the company’s complaint as "a coercive lawsuit aimed at mutual withdrawal of complaints."

4.2. Tactical Assessment of the Company’s Response

The company’s response rests on three pillars:

Legal pressure (criminal complaint + possible damage claims): To intimidate union activity and impose costs.
Selective blocking of negotiation channels (cancellation of May 6 meeting): Using the call disclosure as justification to close the one-on-one channel, shifting to tripartite mediation.
Public opinion framing war (disclosing loss estimates, emphasizing GMP violations): Pressuring the union with the frame "biopharmaceutical quality and safety violation."

This is a typical chaebol labor control playbook, but with an important difference. In Samsung Biologics’ CDMO business, the logical chain "GMP violation → loss of client trust → reduced orders" directly ties to actual business risk. The company’s emphasis on GMP and quality management goes beyond mere PR: it leverages the pharmaceutical industry’s unique regulatory framework as a pressure tool.

4.3. Confirmation of Injunction Outcome

The Incheon District Court’s injunction against the strike was issued before May 1, with no changes reported since. Of the 9 processes for which the company requested a full ban, only 3 (concentration, buffer exchange, drug substance filling) were restricted, while strikes in the other 6 processes were permitted. The company appears not to have filed for an additional injunction, instead shifting its legal response axis toward criminal complaints.

5. Additional Government/Political Intervention

5.1. President Jae-myung Lee’s Remarks and Union Backlash

President Lee, in a senior secretaries’ meeting on April 30, said, "If some organized workers make excessive and unjust demands only to save themselves and receive public criticism, it harms not only that union but also other workers." This was interpreted as targeting unions at Samsung affiliates. On May 2, the Samsung Electronics union issued an official statement refuting this, saying, "Be careful about generalizing."

No additional direct remarks from the President were reported between May 4 and May 7. The presidential office appears to maintain administrative mediation through the Central Regional Employment and Labor Office for the May 8 tripartite meeting, refraining from political intervention. This is consistent with this administration’s labor policy pattern: limited inclusion for small and irregular workers, while for large-firm workers it poses as a "mediator" while effectively maintaining a balance tilted toward capital.

5.2. Political Reactions

On May 1, coinciding with the start of the Samsung Biologics strike, conservative media (Chosun, JoongAng, Dong-A editorials) uniformly reinforced the "union selfishness" frame. The opposition party (People Power Party), led by Representative Dong-hyuk Jang, attacked with claims that "the Samsung union is holding the Korean economy hostage." With local elections approaching in June, the intent to use "hardline union bashing" as an election strategy is evident. If a second Samsung Biologics strike materializes, political intervention is likely to intensify.

5.3. Continued Mediation by Central Regional Employment and Labor Office

Following the May 4 mediation talks, the Central Regional Employment and Labor Office will preside over the May 8 tripartite union-company-government meeting. With the May 6 one-on-one meeting canceled, the May 8 trilateral meeting has effectively become the only institutional channel for resuming negotiations. The mediating capacity of the labor office is now under scrutiny.

6. Outlook for Linkage with Samsung Electronics’ May 21 Strike

6.1. Warning from Board Chairperson Je-yoon Shin

With the Samsung Electronics union announcing a total strike from May 21 for 18 days, a notable message was sent by Samsung Electronics Board Chairperson Je-yoon Shin on May 5 to all employees:

"If the worst-case scenario occurs, both labor and management will lose their ground. It will not only undermine business competitiveness but also cause serious adverse effects on the national economy, including loss of customer trust, losses for shareholders and investors."

Chairperson Shin continued, "In the semiconductor industry, timing and customer trust are paramount. Development and production disruptions and delivery failures caused by a strike can lead to fundamental loss of competitiveness." He warned of "serious damage to the national economy, including tens of billions of dollars in lost exports, tens of trillions of won in lost tax revenue, and GDP contraction." This message, as an official position at the board level, suggests that the company has escalated the strike response to the board level.

6.2. Structural Linkage Between the Two Strikes

The linkage between the Samsung Biologics strike and the Samsung Electronics strike is embedded in the structural design of the super-enterprise union itself. The staggered timing — Samsung Biologics strike (May 1–5 + law-abiding struggle) → Samsung Electronics strike (May 21–June 7) — has the following strategic implications:

Negotiation leverage from the preceding strike: Whether the company makes concessions at Samsung Biologics sets expectations for Samsung Electronics negotiations. Meaningful concessions there would send a positive signal for Samsung Electronics talks. Conversely, if the company holds firm at Samsung Biologics, the Samsung Electronics union’s struggle resolve will intensify.

Test bed for solidarity: The Biologics strike is relatively small (2,800 members, losses of 150–300 billion won) and low-risk. It allows the super-enterprise union to test solidarity capacity, ability to sustain struggle, and public response, thereby refining tactics for the Samsung Electronics strike.

Company’s dispersed pressure: If the Samsung Biologics strike is unresolved when the Samsung Electronics strike begins (May 21), the company must fight on two fronts simultaneously. This is exactly what the union aims for: simultaneous fronts.

6.3. Assessment at the Current Point

The Samsung Biologics first strike sends mixed signals to the Samsung Electronics strike:

Positive signals: 70% participation rate demonstrates strong cohesion. The court’s limited grant of the injunction confirms the legal basis for the right to strike. The union showed confidence by using an aggressive tactic like the call disclosure.
Negative signals: Despite losses of 150 billion won, the company made no substantive concessions and instead countered with a criminal complaint. The May 6 meeting cancellation reveals the fragility of negotiation channels. If no meaningful progress occurs at the May 8 tripartite meeting, the union’s second-strike card becomes a realistic scenario rather than a bluff.

7. Analysis: Strike Outcomes and Class Implications

7.1. Accomplishments of the First Strike

Achievements:

Made visible the historic liquidation of Samsung’s non-union management. The first full-scale strike in 15 years is itself a symbolic achievement. Samsung Biologics workers proved that they are no longer "Samsung men" but a class subject united to demand their interests.
Confirmed the effectiveness of legal strike rights. The Incheon District Court’s permission for strikes in 6 of 9 processes demonstrated that the chaebol’s frame "production halt = public harm" is not legally absolute.
Showed that the super-enterprise union’s solidarity structure works. From Super-Enterprise Union General Chairperson Gwang-heum Hong personally attending the April 22 rally to tactical coordination with the Samsung Electronics union — the structural power of a union spanning affiliates is becoming reality.

Limitations and failures:

Failed to extract substantive concessions from the company. Despite 150 billion won in losses and overwhelming strike participation, the company maintained its position both at the May 4 talks and the May 6 meeting cancellation.
At a disadvantage in the public opinion battle. The conservative media’s "selfishness" frame and "GMP violation" narrative are working effectively. Issues like the union’s demand for consent rights on AI/robot introduction are difficult for the general public to understand and vulnerable to the company’s "management rights infringement" frame.

7.2. Changes in Labor-Management Dynamics

The most significant point in this strike is that labor and management are fighting over corporate governance itself, not just wage negotiations. The union demands prior consent rights on AI/robot introduction, M&A, and performance evaluations. This is not merely a distributive struggle but a control struggle. Workers are attempting to crack capital’s arbitrary management rights and intervene in decision-making on technology adoption and production processes.

It is no accident that the company resists more fiercely over management rights demands than wage increases. Wages can be conceded as a cost, but management rights are something capital cannot yield. Wage increases can be absorbed as costs, but union participation in management erodes capital’s class domination itself.

It is at this point that the strike exposes a fundamental contradiction of Korea’s chaebol system. Samsung Biologics workers create super-profits for the world’s No. 1 CDMO firm, yet they have no control over the distribution of those profits or management methods. In a company with a 46.2% operating profit margin, workers are not even guaranteed job security or fair personnel treatment. The union’s management rights demands are a legitimate response to this contradiction.

7.3. Tactical Assessment of the Law-Abiding Struggle

The law-abiding struggle is a double-edged sword. Strictly adhering to regulations (1) minimizes legal risk, (2) neutralizes the company’s "illegal struggle" frame, and (3) can cause real production disruptions. However, it also (1) reduces strike visibility, weakening public interest, (2) may increase member struggle fatigue if prolonged, and (3) risks being framed as a "slowdown" by the company.

For now, the union’s law-abiding struggle functions as a "pressure maintenance device" until the May 8 tripartite meeting. The real test comes after the 8th.

7.4. Class Implications

Dismissing the Samsung Biologics strike as merely "high-paid large-firm workers’ wage struggle" is a mistake. This strike is labor’s challenge to the core of Korea’s chaebol system.

First, it is a turning point for labor relations across the entire Samsung Group. If the Samsung Biologics strike succeeds, it will be a powerful driver for the Samsung Electronics strike. If it fails, the entire strategy of the super-enterprise union could be shaken.

Second, the management rights demand has important meaning within the comprador-monopoly capitalist analytical framework. Samsung Biologics’ super-profits largely originate from the imperialist conditions of the Biosecure Act (U.S. sanctions toward China). Returning the profits created under such structural conditions to workers is not simply a distributive struggle but an intervention in the profit distribution structure of the imperialist value chain. The union’s demand for management participation is a first step toward democratizing this structure.

Third, the strike reaffirms the class limits of the Lee Jae-myung administration’s labor policy. A progressive government that nonetheless applies a "selfishness" frame to large-firm workers’ collective action reveals the structural limitation of Korean progressive politics: reformism predicated on coexistence with the chaebol.

8. Future Outlook and Points to Watch

8.1. May 8 Tripartite Meeting — Decisive Watershed

The May 8 meeting is essentially the last institutional opportunity for negotiation progress. If no meaningful progress occurs:

The likelihood of a second strike will rise sharply.
The situation will enter a protracted struggle phase leading up to the Samsung Electronics strike on May 21.
Pressure for active government intervention (e.g., presenting a mediation proposal) may grow.

8.2. Key Things to Watch

Whether the company presents a new proposal at the May 8 meeting. Chairperson Park predicted "the company likely won’t present any new proposals," but the official tripartite setting may differ.
Whether the Ministry of Employment and Labor presents a mediation proposal. If the government presents a specific mediation proposal including figures, the reactions of both sides will be critical.
Effectiveness of the law-abiding struggle. For biopharmaceutical processes requiring 24-hour continuous operation, how much production disruption the refusal of overtime and holiday work causes will directly affect the union’s bargaining power.
Progress of the criminal complaint case. If the company files additional complaints, labor relations will further deteriorate.
Samsung Electronics strike preparation trends. Internal dynamics within the Samsung Electronics union (e.g., defections among non-semiconductor division members) may affect Samsung Biologics negotiations.

9. Conclusion

The first Samsung Biologics strike ended without obtaining substantive concessions, but the struggle is not over. The current phase, having shifted to a law-abiding struggle, is merely a temporary lull. Depending on the outcome of the May 8 tripartite meeting, it could lead to a larger clash in the form of a second strike.

The most important advance shown by this strike is that Samsung workers have begun to demand management rights beyond wages. This signifies that the axis of Korea’s labor movement is shifting from distribution to control, from defense to offense. The union’s demand for joint decision-making on AI and robot introduction is a class argument that capital should not unilaterally determine the direction of technological change — labor must intervene.

The company’s hardline response — criminal complaints, blocking negotiation channels, the GMP frame — paradoxically proves how threatening this demand is to capital.

The key question going forward is: Can the super-enterprise union win on the 'small front' of Samsung Biologics and carry that momentum to the 'large front' of Samsung Electronics? May 8 is the first test.

This report is based on publicly available information as of May 7, 2026, 06:56 KST and may be updated as events unfold.